Target
melphalan
9 abstracts
Abstract
Overall survival after isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (the SCANDIUM II trial).Org: University of Gothenburg, Skane University Hospital Comprehensive Cancer Center, University Hospital of Umeå,
Abstract
Melphalan/hepatic delivery system versus best available care in patients with unresectable metastatic uveal melanoma: Randomized FOCUS trial results.Org: Sidney Kimmel Cancer Center, Thomas Jefferson University, Gruppo Multimedica, Charité Hospital Berlin, University Hospital Wuerzburg, University Hospital Giessen and Marburg,
Abstract
Efficacy of carfilzomib-based regimens as induction/consolidation therapy in newly diagnosed multiple myeloma: A meta-analysis.Org: Albany Medical Center Hospital, JT Mather/Northwell Health,
Abstract
High risk neuroblastoma (HR-NB) with MNA and age <18 months: Results from the HR-NBL1/SIOPEN trial.Org: Children’s Cancer Research Institute (CCRI), St. Anna Kinderkrebsforschung GmbH, Schneider Children‘s Medical Center of Israel, Sackler Faculty of Medicine Tel Aviv University, Paediatric Haematology Oncology, Jagiellonian University Medical College, Department of Pediatrics & Adolescent Medicine, Queen Mary Hospital, Karolinska Institutet, Childhood Cancer Research Unit,
Abstract
A multicenter cooperative group study of late effects after high-risk neuroblastoma: COG ALTE15N2—LEAHRN study.Org: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, St. Jude Children's Research Hospital, Children's Oncology Group Statistics and Data Center, University of Florida, Children's Hospital Los Angeles Department of Pediatrics,
Abstract
Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant.Org: Adult Bone Marrow Transplant Service, Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, Myeloma Service, BeyondSpring Pharmaceuticals, Inc.,
Abstract
Busulfan, melphalan, and carfilzomib (BuMelCar) conditioning for autologous stem cell transplant (ASCT) in multiple myeloma: Phase I/II data.Org: Loyola University Medical Center, Maywood, IL,
Abstract
A phase I, randomized, controlled, multicentre trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab in patients with uveal melanoma metastases (the SCANDIUM 2 trial).Org: Department of Surgery, Brigham and Women's Hospital, Boston, MA, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, University of Gothenburg, Gothenburg, Sweden,
Abstract
A novel risk assessment metric for antimyeloma therapies and drug interactions.Org: Kansas State University–Olathe, DATA Consortium, Computational Comparative Medicine, Department of Mathematics, Università degli Studi di Genova, San Martino, Italy, Myeloma Program,